Company intelligence / Profile preview

Jilin Natural Pharmatech

Changchun, Jilin, China

Ownership: Private
Development stage: Other

Overview

Jilin Natural Pharmatech is a Chinese pharmaceutical company focused on the research, development, and commercialization of innovative small molecule drugs and natural product-based therapies. The company primarily targets metabolic diseases, including type 2 diabetes and cardiovascular conditions, with a portfolio that includes SGLT2 inhibitors and DPP4 inhibitors. Based in the Jilin province, the firm leverages regional biodiversity and modern medicinal chemistry to advance its pipeline through various stages of clinical development. Jilin Natural Pharmatech operates with a focus on the domestic Chinese market while seeking to align its R&D standards with international requirements.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Small moleculeNatural products
Industry: Biotech

Beyond the preview

Go deeper on Jilin Natural Pharmatech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jilin Natural Pharmatech.

Explore the full profile